Pfizer (PFE) Stock: European Regulators Accept Lyme Disease Vaccine for Review

Pfizer (PFE) stock trades near $26.80 as European regulators validate Lyme vaccine application after Phase 3 trial shows over 70% efficacy in preventing disease.

The post Pfizer (PFE) Stock: European Regulators Accept Lyme Disease Vaccine for Review appeared first on Blockonomi.